News Feature | February 6, 2014

GlobalData Report: Global Market For Crohn's Disease (CD) Set To Change With New Biologic Therapies

Source: Outsourced Pharma

By Estel Grace Masangkay

The global market for autoimmune disease Crohn’s disease (CD) is set to change with new biologic therapies on the horizon, says the new report from GlobalData. New drugs from Takeda and Johnson & Johnson are expected to challenge existing CD treatment market leaders.

Crohn’s disease is a chronic inflammatory condition of the gastrointestinal tract. CD is a type of inflammatory bowel disease (IBD) where the immune system attacks the affected area of the gut and sets up a chronic inflammation along with ulceration and thickening of the intestinal wall. CD may affect up to 700,000 people in the US alone.

The report focuses on the market dynamics of CD therapeutics and provides a global drug forecast and market analysis from 2012 to 2022. Analysis of current and future market competition in the global CD therapeutics market, as well as key industry drivers, restraints, and challenges are also discussed. Key topics include:

  • Strategic competitor assessment
  • Market characterization
  • Current unmet needs
  • Implications for CD therapeutics markets

According to the report, current biologics treatments for CD consist of tumor necrosis factor (TNF) inhibitors such as Johnson & Johnson’s Remicade (infliximab) and Abbvie’s Humira (adalimumb). Remicade is indicated in adult patients and children (ages 16-17) with moderately to severely active CD and who failed to respond to other therapies. Humira is similarly indicated with the additional recommendation for adult patients who are unable to tolerate or have lost response to infliximab.

New CD therapies such as Takeda’s Entyvio and Johnson & Johnson’s Stelara are poised to take the lead in the face of steadily rising global CD prevalent populations, particularly the anti-TNF refractory portion. Takeda’s vedolizumab is a gut-selective, humanized monoclonal antibody which targets alpha4beta7 (α4β7) integrin to prevent it from interacting and ultimately mediating the inflammatory process that characterizes both CD and ulcerative colitis. CD refractory patients who received Johnson & Johnson’s Stelara treatment likewise showed improvement in a previous clinical trial.

The report says Canada and the emerging Chinese and Indian markets will drive growth in the long term. Each market is forecasted to post positive Compound Annual Growth Rates (CAGRs) in the next decade, chiefly because of the anticipated increasing Remicade uptake during the forecast period.

GlobalData also provides a pipeline analysis of comprehensive data split across various phases, rising new trends, and detailed analysis of pipeline drugs in mid-to-late stages.

The full version of the PharmaPoint: Crohn’s Disease – Global Drug Forecast and Market Analysis to 2022 report can be obtained at Global Markets Direct.